🇪🇺 RETEPLASE in European Union

EMA authorised RETEPLASE on 29 August 1996

Marketing authorisations

EMA — authorised 29 August 1996

  • Application: EMEA/H/C/000106
  • Marketing authorisation holder: Roche Registration Ltd.
  • Local brand name: Ecokinase
  • Indication: Thrombolytic therapy of acute myocardial infarction
  • Status: withdrawn

Read official source →

EMA

  • Application: EMEA/H/C/000105
  • Local brand name: Rapilysin
  • Status: approved

RETEPLASE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is RETEPLASE approved in European Union?

Yes. EMA authorised it on 29 August 1996; EMA has authorised it.

Who is the marketing authorisation holder for RETEPLASE in European Union?

Roche Registration Ltd. holds the EU marketing authorisation.